{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:03Z","timestamp":1786981743861,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T00:00:00Z","timestamp":1508198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11307-017-1133-3","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T11:07:05Z","timestamp":1508238425000},"page":"437-447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Nanostructured Lipid Carrier Co-loaded with Doxorubicin and Docosahexaenoic Acid as a Theranostic Agent: Evaluation of Biodistribution and Antitumor Activity in Experimental Model"],"prefix":"10.1007","volume":"20","author":[{"given":"Renata S.","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana O.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel V.","family":"Mussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1via C. A.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geovanni D.","family":"Cassali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert N.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyelle M.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Colletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas A. M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Rubello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 L. B.","family":"de Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,17]]},"reference":[{"key":"1133_CR1","volume-title":"World cancer report 2014 latest world cancer statistics","author":"BW Stewart","year":"2014","unstructured":"Stewart BW, Wild CP (2014) World cancer report 2014 latest world cancer statistics. International Agency for Research on Cancer, Lyon"},{"key":"1133_CR2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1177\/030089160909500402","volume":"95","author":"L Livi","year":"2009","unstructured":"Livi L, Meattini I, de Cardillo CL et al (2009) Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: a retrospective analysis. Tumori 95:422\u2013426","journal-title":"Tumori"},{"key":"1133_CR3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00059-011-3470-3","volume":"36","author":"Y Shi","year":"2011","unstructured":"Shi Y, Moon M, Dawood S et al (2011) Mechanisms and management of doxorubicin cardiotoxicity. Herz 36:296\u2013305","journal-title":"Herz"},{"key":"1133_CR4","doi-asserted-by":"crossref","first-page":"8782","DOI":"10.1158\/1078-0432.CCR-05-1664","volume":"27","author":"AJ Primeau","year":"2005","unstructured":"Primeau AJ, Rendon A, Hedley D et al (2005) The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 27:8782\u20138788","journal-title":"Clin Cancer Res"},{"key":"1133_CR5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","volume":"99","author":"O Tr\u00e9dan","year":"2007","unstructured":"Tr\u00e9dan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441\u20131454","journal-title":"J Natl Cancer Inst"},{"key":"1133_CR6","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho C, Santos RX, Cardoso S et al (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267\u20133285","journal-title":"Curr Med Chem"},{"key":"1133_CR7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","volume":"19","author":"J Jassem","year":"2001","unstructured":"Jassem J, Pie\u0144kowski T, P\u0142uza\u0144ska A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707\u20131715","journal-title":"J Clin Oncol"},{"key":"1133_CR8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<578::AID-IJC14>3.0.CO;2-5","volume":"75","author":"E Germain","year":"1998","unstructured":"Germain E, Chaj\u00e8s V, Cognault S et al (1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231: relationship to lipid peroxidation. Int J Cancer 75:578\u2013583","journal-title":"Int J Cancer"},{"key":"1133_CR9","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1158\/1078-0432.CCR-06-0386","volume":"12","author":"S Colas","year":"2006","unstructured":"Colas S, Mah\u00e9o K, Denis F et al (2006) Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin Cancer Res 12:5879\u20135886","journal-title":"Clin Cancer Res"},{"key":"1133_CR10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/biof.181","volume":"37","author":"RA Siddiqui","year":"2011","unstructured":"Siddiqui RA, Harvey KA, Xu Z et al (2011) Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. Biofactors 37:399\u2013412","journal-title":"Biofactors"},{"key":"1133_CR11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.freeradbiomed.2005.04.023","volume":"39","author":"K Mah\u00e9o","year":"2005","unstructured":"Mah\u00e9o K, Vibet S, Steghens JP et al (2005) Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 39:742\u2013751","journal-title":"Free Radic Biol Med"},{"key":"1133_CR12","first-page":"2041","volume":"7","author":"WE Hardman","year":"2001","unstructured":"Hardman WE, Avula CP, Fernandes G, Cameron IL (2001) Three percent dietary fish oil concentrate increased efficacy of doxorubicin against MDA-MB 231 breast cancer xenografts. Clin Cancer Res 7:2041\u20132049","journal-title":"Clin Cancer Res"},{"key":"1133_CR13","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.drudis.2012.05.010","volume":"17","author":"P Parhi","year":"2012","unstructured":"Parhi P, Mohanty C, Sahoo SK (2012) Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today 17:1044\u20131052","journal-title":"Drug Discov Today"},{"key":"1133_CR14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1368-7646(03)00082-7","volume":"6","author":"C Mamot","year":"2003","unstructured":"Mamot C, Drummond DC, Hong K et al (2003) Liposome-based approaches to overcome anticancer drug resistance. Drug Resist Update 6:271\u2013279","journal-title":"Drug Resist Update"},{"key":"1133_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH Muller","year":"2000","unstructured":"Muller RH, Mader K, Gohla D (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014a review of the state of the art. Eur J Pharm Biopharm 50:161\u2013177","journal-title":"Eur J Pharm Biopharm"},{"key":"1133_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","volume":"47","author":"W Mehnert","year":"2001","unstructured":"Mehnert W, Mader K (2001) Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165\u2013196","journal-title":"Adv Drug Deliv Rev"},{"key":"1133_CR17","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.addr.2010.08.004","volume":"62","author":"SM Janib","year":"2010","unstructured":"Janib SM, Moses AS, MacKay JA (2010) Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev 62:1052\u20131063","journal-title":"Adv Drug Deliv Rev"},{"key":"1133_CR18","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.7150\/thno.15335","volume":"6","author":"SD Jo","year":"2016","unstructured":"Jo SD, SH K, Won Y-Y et al (2016) Targeted nanotheranostics for future personalized medicine: recent progress in cancer therapy. Theranostics 6:1362\u20131377","journal-title":"Theranostics"},{"key":"1133_CR19","first-page":"330","volume":"4","author":"KY Choi","year":"2012","unstructured":"Choi KY, Liu G, Lee S, Chen X (2012) Theranosticnanoplatforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nano 4:330\u2013342","journal-title":"Nano"},{"key":"1133_CR20","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.addr.2010.07.009","volume":"62","author":"J Xie","year":"2010","unstructured":"Xie J, Chen X (2010) Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 62:1064\u20131079","journal-title":"Adv Drug Deliv Rev"},{"key":"1133_CR21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1148\/radiol.2262011811","volume":"226","author":"DJ Yang","year":"2003","unstructured":"Yang DJ, Kim C, Schechter NR et al (2003) Imaging with 99mTc-ECDG targeted at the multifunctional glucose system: feasibility studies with rodents. Radiology 226:465\u2013473","journal-title":"Radiology"},{"key":"1133_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-4419-5860-0_6","volume-title":"Fundamentals of nuclear pharmacy","author":"GB Saha","year":"2010","unstructured":"Saha GB (2010) Radiopharmaceuticals and methods of radiolabeling. In: Fundamentals of nuclear pharmacy. Springer, New York, pp 83\u2013113"},{"key":"1133_CR23","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s11095-013-1290-2","volume":"8","author":"SV Mussi","year":"2014","unstructured":"Mussi SV, Sawant R, Perche F et al (2014) Novel nanostructured lipid carrier co-loaded with doxorubicin and docosahexaenoic acid demonstrates enhanced in vitro activity and overcomes drug resistance in MCF-7\/Adr cells. Pharm Res 8:1882\u20131890","journal-title":"Pharm Res"},{"key":"1133_CR24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejps.2012.10.025","volume":"48","author":"SV Mussi","year":"2013","unstructured":"Mussi SV, Silva RC, Oliveira MC et al (2013) New approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 48:282\u2013290","journal-title":"Eur J Pharm Sci"},{"key":"1133_CR25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MNM.0000000000000443","volume":"37","author":"RS Fernandes","year":"2016","unstructured":"Fernandes RS, Silva JO, Lopes SCA et al (2016) Technetium-99m-labeled doxorubicin as an imaging probe for murine breast tumor (4T1 cell line) identification. Nucl Med Commun 37:307\u2013312","journal-title":"Nucl Med Commun"},{"key":"1133_CR26","volume-title":"Medicina Nuclear","author":"JH Thrall","year":"2003","unstructured":"Thrall JH, Ziessman HA (2003) Medicina Nuclear, 2nd edn. Guanabara Koogan, Rio de Janeiro","edition":"2"},{"key":"1133_CR27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.biopha.2012.04.005","volume":"66","author":"CM Souza","year":"2012","unstructured":"Souza CM, Carvalho LF, Vieira TS et al (2012) Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. Biomed Pharmacother 66:491\u2013498","journal-title":"Biomed Pharmacother"},{"key":"1133_CR28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.addr.2011.04.006","volume":"64","author":"Y Li","year":"2012","unstructured":"Li Y, Wang J, Wientjes MG, JL A (2012) Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 64:29\u201339","journal-title":"Adv Drug Deliv Rev"},{"key":"1133_CR29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa J, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271\u2013284","journal-title":"J Control Release"},{"key":"1133_CR30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","volume":"63","author":"V Torchilin","year":"2011","unstructured":"Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131\u2013135","journal-title":"Adv Drug Deliv Rev"},{"key":"1133_CR31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jconrel.2005.02.028","volume":"105","author":"LH Reddy","year":"2005","unstructured":"Reddy LH, Sharma LK, Chuttani K et al (2005) Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton\u2019s lymphoma tumor bearing mice. J Control Release 105:185\u2013198","journal-title":"J Control Release"},{"key":"1133_CR32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2013.01.029","volume":"84","author":"A Beloqui","year":"2013","unstructured":"Beloqui A, Solinis MA, Delgado A et al (2013) Biodistribution of nnostructured lipid carriers (NLCs) after intravenous administration to rats: influence of technological fators. Eur J Pharm Biopharm 84:309\u2013314","journal-title":"Eur J Pharm Biopharm"},{"key":"1133_CR33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ejpb.2008.09.026","volume":"71","author":"V Torchilin","year":"2009","unstructured":"Torchilin V (2009) Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71:431\u2013444","journal-title":"Eur J Pharm Biopharm"},{"key":"1133_CR34","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan F, Dellian M, Fukumura D et al (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752\u20133756","journal-title":"Cancer Res"},{"key":"1133_CR35","first-page":"4324","volume":"60","author":"AJ Leu","year":"2000","unstructured":"Leu AJ, Berk DA, Lymboussaki A et al (2000) Absence of functional lymphatics within murine sarcoma: molecular and functional evaluation. Cancer Res 60:4324\u20134327","journal-title":"Cancer Res"},{"key":"1133_CR36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:246\u2013257","journal-title":"Nature"},{"key":"1133_CR37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1359-6446(03)02686-2","volume":"8","author":"II Munn","year":"2003","unstructured":"Munn II (2003) Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8:396\u2013403","journal-title":"Drug Discov Today"},{"key":"1133_CR38","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1073\/pnas.0800835105","volume":"105","author":"K Gosh","year":"2008","unstructured":"Gosh K, Thodeti CK, Dudley AC et al (2008) Tumor-derived endothelial cells exhibit aberrant Rhon-mediated mechanosensing and abnormal angiogenesis in vitro. Proc Natl Acad Sci U S A 105:11305\u201311310","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1133_CR39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jconrel.2015.01.033","volume":"118","author":"EM Mastria","year":"2015","unstructured":"Mastria EM, Chen M, McDaniel JR (2015) Doxorubicin-conjugated polypeptide nanoparticles inhibit metastasis in two murine models of carcinoma. J Control Release 118:52\u201358","journal-title":"J Control Release"},{"key":"1133_CR40","doi-asserted-by":"crossref","first-page":"46737","DOI":"10.1039\/C4RA07453J","volume":"4","author":"L Sun","year":"2014","unstructured":"Sun L, Deng X, Yang X et al (2014) Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma. RSC Adv 4:46737\u201346750","journal-title":"RSC Adv"},{"key":"1133_CR41","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/mabi.201500043","volume":"15","author":"J Wang","year":"2015","unstructured":"Wang J, Ma W, Tu W (2015) Synergistically improved anti-tumor efficacy by co-delivery doxorubicin and curcumin polymeric micelles. Macromol Biosci 15:1252\u20131261","journal-title":"Macromol Biosci"},{"key":"1133_CR42","first-page":"1863","volume":"44","author":"MM Guffy","year":"1984","unstructured":"Guffy MM, North JA, Burns CP (1984) Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res 44:1863\u20131866","journal-title":"Cancer Res"},{"key":"1133_CR43","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.addr.2003.12.002","volume":"56","author":"SA Wissing","year":"2004","unstructured":"Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257\u20131272","journal-title":"Adv Drug Deliv Rev"},{"key":"1133_CR44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urolonc.2007.03.015","volume":"26","author":"B Haley","year":"2008","unstructured":"Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26:57\u201364","journal-title":"Urol Oncol"},{"key":"1133_CR45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"26","author":"MER O\u2019Brien","year":"2004","unstructured":"O\u2019Brien MER, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\u2122\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 26:440\u2013449","journal-title":"Ann Oncol"},{"key":"1133_CR46","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1021\/mp500093c","volume":"14","author":"AJ Shuhendler","year":"2014","unstructured":"Shuhendler AJ, Prasad P, Zhang RX et al (2014) Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmuno compromised breast tumor model. Mol Pharmaceutics 14:2659\u20132674","journal-title":"Mol Pharmaceutics"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-017-1133-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-017-1133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-017-1133-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T22:10:20Z","timestamp":1603145420000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-017-1133-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,17]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1133"],"URL":"https:\/\/doi.org\/10.1007\/s11307-017-1133-3","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,17]]}}}